DR Reddy's Laboratories (RDY) closed at $14.15 on October 28, 2026, up 2.9% from the previous close, on volume of 3,096,543 shares (30-day average 3,091,203).
Data as of October 28, 2026.
Dr. Reddy’s Gets Favorable USFDA VAI Status at Srikakulam Plant
TipRanks (Thu, 29-Oct 6:36 AM ET)
Analysts Offer Insights on Healthcare Companies: Dr Reddy’s Laboratories (RDY) and Genmab (GMAB)
TipRanks (Mon, 26-Oct 11:20 AM ET)
Dr. Reddy’s Files Unmodified Auditor Review on September 2026 Interim Results
TipRanks (Mon, 26-Oct 6:47 AM ET)
Dr. Reddy’s Files Form 6-K, Publishes Q2 FY27 Earnings Call Recordings
TipRanks (Mon, 26-Oct 6:47 AM ET)
Improving Margins and EPS Upgrades Offset by Full Valuation, Supporting Hold Rating
TipRanks (Mon, 26-Oct 1:55 AM ET)
PRNewswire (Thu, 24-Sep 6:39 PM ET)
Business Wire (Thu, 20-Aug 11:00 AM ET)
Business Wire (Thu, 20-Aug 9:00 AM ET)
Business Wire (Wed, 19-Aug 6:17 PM ET)
Business Wire (Thu, 13-Aug 8:00 PM ET)
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
DR Reddy's Laboratories trades on the NYSE stock market under the symbol RDY.
As of October 29, 2026, RDY stock price climbed to $14.28 with 153,933 million shares trading.
RDY has a beta of -0.26, meaning it tends to be less sensitive to market movements. RDY has a correlation of 0.01 to the broad based SPY ETF.
RDY has a market cap of $11.90 billion. This is considered a Large Cap stock.
Last quarter DR Reddy's Laboratories reported $905 million in Revenue and $.12 earnings per share. This fell short of revenue expectation by $-76 million and missed earnings estimates by -$.04.
In the last 3 years, RDY traded as high as $84.46 and as low as $11.36.
The top ETF exchange traded funds that RDY belongs to (by Net Assets): EMOP, AVEM, VWO, SPEM, VXUS.
RDY has underperformed the market in the last year with a return of -1.0%, while SPY returned +13.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RDY shares. However, RDY has outperformed the market in the last 3 month and 2 week periods, returning +21.7% and +12.0%, while SPY returned +4.1% and 0.0%, respectively. This indicates RDY has been having a stronger performance recently.
RDY support price is $13.91 and resistance is $14.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RDY shares will trade within this expected range on the day.
